Nadine Besson

1.2k total citations
16 papers, 800 citations indexed

About

Nadine Besson is a scholar working on Genetics, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Nadine Besson has authored 16 papers receiving a total of 800 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 16 papers in Hematology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Nadine Besson's work include Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Acute Lymphoblastic Leukemia research (8 papers). Nadine Besson is often cited by papers focused on Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Acute Lymphoblastic Leukemia research (8 papers). Nadine Besson collaborates with scholars based in United States, France and Italy. Nadine Besson's co-authors include Dong‐Wook Kim, H. Jean Khoury, Jörge E. Cortes, Carlo Gambacorti‐Passerini, Eric Leip, Tim H. Brümmendorf, Hagop M. Kantarjian, Virginia Kelly, Steven Arkin and Anna Turkina and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia Research.

In The Last Decade

Nadine Besson

16 papers receiving 786 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nadine Besson United States 6 701 598 308 144 107 16 800
Н Д Хорошко Russia 8 767 1.1× 651 1.1× 511 1.7× 126 0.9× 77 0.7× 13 883
D-W Kim Australia 4 767 1.1× 601 1.0× 369 1.2× 144 1.0× 69 0.6× 4 821
Angela Volkert United States 6 366 0.5× 313 0.5× 163 0.5× 122 0.8× 59 0.6× 16 480
Alessandra Gnani Italy 7 727 1.0× 597 1.0× 405 1.3× 70 0.5× 157 1.5× 16 788
Sara Dellasala United States 11 622 0.9× 388 0.6× 149 0.5× 92 0.6× 91 0.9× 33 695
Fabrizio Ciccone Italy 8 460 0.7× 403 0.7× 208 0.7× 81 0.6× 89 0.8× 13 574
А К Голенков Russia 7 369 0.5× 239 0.4× 185 0.6× 104 0.7× 28 0.3× 16 451
J. Janssen Netherlands 9 285 0.4× 222 0.4× 111 0.4× 70 0.5× 49 0.5× 11 412
Heather A. Bradeen United States 6 262 0.4× 217 0.4× 168 0.5× 65 0.5× 52 0.5× 7 400
Emilie Leroy Belgium 13 385 0.5× 514 0.9× 150 0.5× 139 1.0× 23 0.2× 19 650

Countries citing papers authored by Nadine Besson

Since Specialization
Citations

This map shows the geographic impact of Nadine Besson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadine Besson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadine Besson more than expected).

Fields of papers citing papers by Nadine Besson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadine Besson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadine Besson. The network helps show where Nadine Besson may publish in the future.

Co-authorship network of co-authors of Nadine Besson

This figure shows the co-authorship network connecting the top 25 collaborators of Nadine Besson. A scholar is included among the top collaborators of Nadine Besson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadine Besson. Nadine Besson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Kantarjian, Hagop M., Jörge E. Cortes, Dong‐Wook Kim, et al.. (2013). Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 123(9). 1309–1318. 111 indexed citations
2.
Hsyu, Poe‐Hirr, Karı̈n Gogat, Ladan Duvillié, Virginia Kelly, & Nadine Besson. (2012). Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia. Blood. 120(21). 4440–4440. 1 indexed citations
3.
Khoury, H. Jean, Carlo Gambacorti‐Passerini, Hagop M. Kantarjian, et al.. (2012). Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update. Blood. 120(21). 3785–3785. 3 indexed citations
4.
5.
Brümmendorf, Tim H., Carlo Gambacorti‐Passerini, Philippe Schafhausen, et al.. (2012). Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).. Journal of Clinical Oncology. 30(15_suppl). 6511–6511. 4 indexed citations
6.
Cortes, Jörge E., Hagop M. Kantarjian, Dong‐Wook Kim, et al.. (2012). Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update. Blood. 120(21). 3779–3779. 4 indexed citations
7.
Khoury, H. Jean, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2012). Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 119(15). 3403–3412. 228 indexed citations
8.
Trask, Peter C., David Cella, Nadine Besson, et al.. (2011). Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leukemia Research. 36(4). 438–442. 48 indexed citations
9.
Khoury, H. Jean, Jörge E. Cortes, Carlo Gambacorti‐Passerini, et al.. (2011). Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors. Blood. 118(21). 110–110. 5 indexed citations
10.
Brümmendorf, Tim H., Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2011). Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).. Journal of Clinical Oncology. 29(15_suppl). 6535–6535. 5 indexed citations
11.
Cortes, Jörge E., Hagop M. Kantarjian, Tim H. Brümmendorf, et al.. (2011). Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 118(17). 4567–4576. 348 indexed citations
12.
Kantarjian, Hagop M., Jörge E. Cortes, Dong‐Wook Kim, et al.. (2011). Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors. Blood. 118(21). 2760–2760. 3 indexed citations
13.
Gambacorti‐Passerini, Carlo, H. Jean Khoury, Hélio Pinczowski, et al.. (2010). Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.. Blood. 116(21). 3434–3434. 4 indexed citations
14.
Khoury, H. Jean, et al.. (2010). Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).. Journal of Clinical Oncology. 28(15_suppl). 6514–6514. 2 indexed citations
15.
Khoury, H. Jean, Dong‐Wook Kim, Andrey Zaritskey, et al.. (2010). Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib. Blood. 116(21). 892–892. 2 indexed citations
16.
Gambacorti‐Passerini, Carlo, Jörge E. Cortes, H. Jean Khoury, et al.. (2010). Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.. Journal of Clinical Oncology. 28(15_suppl). 6509–6509. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Н Д Хорошко Breakdown of academic impact, for papers by D-W Kim Breakdown of academic impact, for papers by Angela Volkert Breakdown of academic impact, for papers by Alessandra Gnani Breakdown of academic impact, for papers by Sara Dellasala Breakdown of academic impact, for papers by Fabrizio Ciccone Breakdown of academic impact, for papers by А К Голенков Breakdown of academic impact, for papers by J. Janssen Breakdown of academic impact, for papers by Heather A. Bradeen Breakdown of academic impact, for papers by Emilie Leroy
Rankless by CCL
2026